Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conferenceadmin2022-01-05T13:08:05-05:00January 6th, 2022|Press Release| Read More
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessationadmin2022-01-03T16:19:35-05:00January 4th, 2022|Press Release| Read More
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Developmentadmin2021-12-21T22:48:17-05:00December 22nd, 2021|Press Release| Read More
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessationadmin2021-11-22T15:02:03-05:00November 23rd, 2021|Press Release| Read More
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)admin2021-11-21T20:05:19-05:00November 22nd, 2021|Press Release| Read More
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Developmentadmin2021-11-09T14:09:55-05:00November 9th, 2021|Press Release| Read More
Achieve Life Sciences Announces Participation in November Investor Conferencesadmin2021-11-03T20:09:05-05:00November 4th, 2021|Press Release| Read More
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessationadmin2021-11-01T16:35:00-05:00November 2nd, 2021|Press Release| Read More
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021admin2021-10-25T14:20:27-05:00October 26th, 2021|Press Release| Read More
Achieve Life Sciences to Participate in Upcoming Investor Conferencesadmin2021-09-09T13:30:32-05:00September 15th, 2021|Press Release| Read More